Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

STAT3 degrader KT-333

A heterobifunctional small molecule degrader of the protein signal transducer and activator of transcription 3 (STAT3) composed of a STAT3-binding moiety and a E3 ligase-binding moiety, with potential antineoplastic activity. Upon administration, the STAT3 degrader KT-333 specifically targets and binds to STAT3, thereby targeting STAT3 for degradation. Upon binding, endogenous E3 ubiquitin ligase is then recruited to STAT3 by the E3 ligase recognition moiety of KT-333, resulting in the tagging of STAT3 by ubiquitin. This causes ubiquitination and degradation of STAT3 by the proteasome, and prevents STAT3 activation, STAT3-mediated signaling and the expression of STAT3 target genes. This inhibits the proliferation of STAT3-overexpressing tumor cells. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.
Code name:KT 333
KT-333
KT333
Search NCI's Drug Dictionary